3SASAMURA H.Prevention of hypertensive renal damage by prepubertal treatment with ARB[J].Nippon Rinsho,2002,60(10):1962-1967.
二级参考文献8
1Grandi A M, Santillo R, Zanzi P, et al. Microalbuminurina in never-treated hypertensives: Lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. Am J Hypertens, 2000, 13(4 Pt 1) .. 353--358.
2Tierney W M, Harris L E, Copley J B, et al. Effect of hypertension and type IT diabetes on renal function in an urban population. Am J Hypertens, 1990, 3:69--75.
3Messerli F H, Garavaglia G E, Schmieder R E, et al.Disparate cardiovascular finding in man and woman with essential hypertension. Ann Intern Med, 1987, 107:158--161.
4James M A, Fotherby M D, Potter J F. Microalbuminuria in elderly hypertensives: Reproducibility and relation to clinic and ambulatory blood pressure. J Hypertens, 1994, 12:309--313.
5Mancia G, Parati G. The role of ambulatory blood pressure monitoring in elderly hypertensive patients.Blood Press, 2000,2:12--16.
6Porush J G. Hypertension and chronic renal failure:The use of ACE inhibitors. Am J Kidney Dis, 1998,31 : 177-- 184.
8Lewis E,Hunsicker LG,Clarke WR. Renoprotective effect of the an- giotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J]. N Engl J Med ,2001,345(12) :851-860.
9Reddy RB,Sudhakar S, Sridhar C,et al. Process fnr preparing of irbesar- tan [P]. WO Patent 2005113518,2005-12-01.
10Murali K,Prasad D. Process for the preparation of irbesartan [P]. US Patent 0275828,2011-11-10.
